Eton Pharmaceuticals, Inc. ETON
57.68
(1.81)
(3.04%)
as of 25 Sep
- Market cap
- $1.7B
- P/E
- 123×
Follow ETON
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(34.17%) | (18.19%) | (5.36%) | 35.97% | |
| (9.52%) | (5.47%) | (1.62%) | 11.67% | ||
ROIC |
(10.23%) | (1.71%) | 3.06% | 21.39% | |
Return on Tangible Assets |
(23.77%) | (20.52%) | (15.63%) | 53.25% | |
Average Days of Receivables |
67.91 | 53.67 | 56.29 | 86.02 | |
Free Cash Flow per Share |
0.78 | 0.38 | (0.28) | (0.30) | |
Free Cash Flow |
21.01 | 10.18 | (7.70) | (8.39) | |
Capital Expenditures |
(0.30) | (0.34) | (23.54) | (23.52) | |
Piotroski F-Score |
4.00 | 5.00 | 5.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
23.52% | 12.73% | 19.55% | 14.94% | |
Accounts Receivable Turnover |
7.53 | 9.34 | 5.83 | 5.37 | |
Accounts Payable Turnover |
4.04 | 4.91 | 4.28 | 3.35 | |
Inventory Turnover |
3.64 | 2.43 | 2.80 | 2.62 | |
Average Days of Payables |
152.18 | 107.67 | 125.18 | 118.17 | |
Days of Inventory on Hand |
179.89 | 151.25 | 134.29 | 83.21 | |
Tax Rate |
0.03 | 0.01 | (0.01) | 0.00 | |
Research and Development Expense of Revenue |
7.27% | 9.71% | 9.75% | 5.45% | |
Selling, General and Administrative Expense of Revenue |
47.90% | 44.80% | 42.67% | 36.97% | |
Share Based Compensation of Revenue |
7.35% | 6.89% | 6.71% | 4.93% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(3.19) | (2.29) | (10.74) | 1.19 | |
Depreciation/Fixed assets |
16.81 | 14.54 | 12.59 | 14.70 | |
Capex/Depreciation |
(0.06) | (0.07) | (5.03) | (4.55) | |
Revenue per Share |
2.61 | 2.97 | 3.19 | 3.82 | |
Operating CF per Share |
0.79 | 0.39 | 0.58 | 0.55 | |
Capex per Share |
(0.01) | (0.01) | (0.86) | (0.85) | |
Capex to Sales |
0.00 | 0.00 | 0.27 | 0.22 | |
Net Profit Margin |
(9.50%) | (5.75%) | (1.70%) | 12.02% |
Columns are period end dates